Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Selonsertib did not improve liver fibrosis more than a placebo.
The placebo-controlled trial Phase III trial of selonsertib had sought to improve fibrosis while not worsening NASH.
The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...
Highlights from the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston
The drug improved several measures of liver disease severity among those with non-alcoholic steatohepatitis in a clinical trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.